Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of PA21 versus sevelamer carbonate in dialysis patients with hyperphosphataemia
2010-022012-40Phase 3Completed
- Sponsor
- CSL Vifor
- Start
- Oct 2010
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Sucroferric oxyhydroxide in hyperphosphatemia (2 arms), sponsored by CSL Vifor. Primary endpoint: Adverse events profile and routine biochemical/haematological parameters. Started Oct 2010; status: completed.
02
Drugs
Sucroferric oxyhydroxide
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on 2010-022012-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022012-40.